CN113549096A - 一种烷烃链侨联Aβ抑制剂的荧光探针及其制备方法 - Google Patents
一种烷烃链侨联Aβ抑制剂的荧光探针及其制备方法 Download PDFInfo
- Publication number
- CN113549096A CN113549096A CN202110799676.1A CN202110799676A CN113549096A CN 113549096 A CN113549096 A CN 113549096A CN 202110799676 A CN202110799676 A CN 202110799676A CN 113549096 A CN113549096 A CN 113549096A
- Authority
- CN
- China
- Prior art keywords
- alkane
- fluorescent probe
- inhibitor
- molar ratio
- beta inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 30
- 150000001335 aliphatic alkanes Chemical group 0.000 title claims abstract description 17
- 239000000523 sample Substances 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title abstract description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims abstract description 30
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 23
- 239000002904 solvent Substances 0.000 claims abstract description 20
- 238000003756 stirring Methods 0.000 claims abstract description 17
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims abstract description 15
- 239000003054 catalyst Substances 0.000 claims abstract description 13
- 239000012265 solid product Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 238000002390 rotary evaporation Methods 0.000 claims abstract description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 12
- 238000003786 synthesis reaction Methods 0.000 claims description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims description 8
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims description 6
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 4
- 235000008777 kaempferol Nutrition 0.000 claims description 4
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims description 4
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 4
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 claims description 4
- OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical compound CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 claims description 3
- LVUHGUOLNPWELF-UHFFFAOYSA-N 4,5-dimethyl-3,6-dioxocyclohexa-1,4-diene-1,2-dicarbonitrile Chemical compound CC1=C(C)C(=O)C(C#N)=C(C#N)C1=O LVUHGUOLNPWELF-UHFFFAOYSA-N 0.000 claims description 3
- GHKLSRUKZUYUAD-UHFFFAOYSA-N 4-ethyl-2-hydroxybenzaldehyde Chemical compound CCC1=CC=C(C=O)C(O)=C1 GHKLSRUKZUYUAD-UHFFFAOYSA-N 0.000 claims description 3
- 239000007832 Na2SO4 Substances 0.000 claims description 3
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 229940109262 curcumin Drugs 0.000 claims description 3
- 235000012754 curcumin Nutrition 0.000 claims description 3
- 239000004148 curcumin Substances 0.000 claims description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 3
- 239000012429 reaction media Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 229940016667 resveratrol Drugs 0.000 claims description 3
- 235000021283 resveratrol Nutrition 0.000 claims description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
- 239000001361 adipic acid Substances 0.000 claims description 2
- 235000011037 adipic acid Nutrition 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- OVTCUIZCVUGJHS-UHFFFAOYSA-N dipyrrin Chemical group C=1C=CNC=1C=C1C=CC=N1 OVTCUIZCVUGJHS-UHFFFAOYSA-N 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- BVBRZOLXXOIMQG-UHFFFAOYSA-N fluoroborane Chemical compound FB BVBRZOLXXOIMQG-UHFFFAOYSA-N 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 claims description 2
- 125000006617 triphenylamine group Chemical class 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 17
- 230000035772 mutation Effects 0.000 abstract description 3
- 229920001184 polypeptide Polymers 0.000 abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 3
- 230000008499 blood brain barrier function Effects 0.000 abstract description 2
- 210000001218 blood-brain barrier Anatomy 0.000 abstract description 2
- 210000003169 central nervous system Anatomy 0.000 abstract description 2
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 238000005886 esterification reaction Methods 0.000 abstract description 2
- 230000010354 integration Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 108010016626 Dipeptides Proteins 0.000 description 9
- SAUDSWFPPKSVMK-LBPRGKRZSA-N (2s)-2-(n-phenylanilino)propanoic acid Chemical compound C=1C=CC=CC=1N([C@@H](C)C(O)=O)C1=CC=CC=C1 SAUDSWFPPKSVMK-LBPRGKRZSA-N 0.000 description 7
- 239000002121 nanofiber Substances 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 6
- 230000005311 nuclear magnetism Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000001384 succinic acid Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000012634 optical imaging Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- LUKBXSAWLPMMSZ-UHFFFAOYSA-N resveratrol Chemical compound C1=CC(O)=CC=C1C=CC1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-UHFFFAOYSA-N 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- YCMLQMDWSXFTIF-UHFFFAOYSA-N 2-methylbenzenesulfonimidic acid Chemical compound CC1=CC=CC=C1S(N)(=O)=O YCMLQMDWSXFTIF-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/022—Boron compounds without C-boron linkages
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1007—Non-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1014—Carbocyclic compounds bridged by heteroatoms, e.g. N, P, Si or B
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1044—Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms
- C09K2211/1055—Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms with other heteroatoms
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1088—Heterocyclic compounds characterised by ligands containing oxygen as the only heteroatom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明涉及一种烷烃链侨联Aβ抑制剂的荧光探针及其制备方法,包括以下步骤:Aβ抑制剂(M)、DCC/DMAP按照摩尔比1:0.1~1/0.1~1溶解到氯仿中,加入1~1.3当量含有烷烃链的(M:M)Linker,50~100℃搅拌1~6h,25℃~60℃真空旋蒸除去溶剂,采用层析柱分离提纯,得到固体产物M‑Ln;NB与M‑Ln按照摩尔比1:1~3溶解到氯仿中,加入0.1~1当量(M:M)催化剂B。采用近红外荧光探针与含有烷烃链的连桥侨联Aβ抑制剂通过酯化反应结合,其中近红外荧光特性区别于生物组织自身荧光信号,并对阿尔兹海默症早期发生的多肽区域突变位点FF有效识别结合呈现荧光,近红外荧光标记含有烷烃链连桥侨联的Aβ抑制剂后协同作用使得该近红外荧光探针能跨越血脑屏障,到达中枢神经系统,能够实现对AD早期诊疗一体化。
Description
技术领域
本发明属于有机合成技术领域,具体涉及一种烷烃链侨联Aβ抑制剂的荧光探针及其制备方法。
背景技术
尽管全球对阿尔茨海默病(AD)的研究已有100多年,但目前仍缺乏有效的治疗手段。早期诊断技术的缺乏,使得AD治疗药物在开发时往往选取已出现明显症状的中晚期患者,此时患者脑内已积累了大量不可逆转的神经损伤,这被认为是AD药物研发高失败率的主要原因之一。目前AD的临床诊断主要基于NINCDS-ADRDA定义的AD诊断标准、患者家族疾病史以及临床表现,因此诊断往往缺乏准确性。伴随AD发病机制的研究,β–淀粉样蛋白(Aβ)及其聚集状态的作用成为了研究重点。Aβ寡聚体和Aβ纤维分别与AD的早期和晚期相关,因而研究选择性靶向不同聚集状态的Aβ荧光探针有望开发可用于AD早期发现和监测的诊断工具。光学成像因其具有无创,非辐射,价格低廉、可实时进行体内外多靶点监测等优势而受到广泛关注。光学成像最大的不足是难以达到检测所需的穿透深度,而波长范围在650~900nm的近红外光具有较好的穿透深度,能够适应体内检测需求,且该波长范围下生物物质的自荧光干扰最小,对生物样品的光损伤也最小;目前已有多个近红外荧光探针被开发用于体内检测,但是主要应用于肿瘤成像领域,因此开发可用于对Aβ有着很好靶向抑制作用同时拥有良好的灵敏度、较高的亲和力和早期检测能力的新型荧光探针对AD的早期诊断与治疗具有极大的研究意义和挑战性。
发明内容
本发明的主要目的在于提供一种对β-淀粉样蛋白起到靶向抑制作用、高灵敏度、高选择性的阿尔兹海默症早期诊断治疗荧光探针,可以有效解决背景技术中的问题。
为实现上述目的,本发明提供如下技术方案:一种烷烃链侨联Aβ抑制剂的荧光探针(NB-Cn-M),其特征在于,其分子结构式为:
式中二吡咯甲川氟硼络合物的8位有一个与Aβ抑制剂(M)侨联的苯基取代基、1,7-位有两个烷基,3,5-位有两个三苯胺,Aβ抑制剂(M)具体为山柰酚、姜黄素和白藜芦醇中的任一种。
其反应路线如下式所示:
一种烷烃链侨联Aβ抑制剂的荧光探针(NB-Cn-M)的制备方法,其特征在于,包括如下步骤:
(1)将甲基吡咯、对-乙羟基苯甲醛按照摩尔比2~3:1~1.5混合溶解到二氯甲烷中,加入1~1.3当量三乙胺(M:M),室温搅拌1h~6h,冰浴中缓慢滴加1~3当量的三氟化硼乙醚(M:M),搅拌0.5~3h,加入1~3当量的2,3-二甲基-5,6-二氰基苯醌,二氯甲烷萃取,无水Na2SO4干燥,真空除去溶剂,采用层析柱分离提纯,得到橙黄色固体产物BODIPY;
将BODIPY、4-N,N-二苯基胺苯甲醛、催化剂A按照摩尔比1~1.3:2~2.3:0.1~1溶于甲苯和哌啶的混合溶液中(v/v:1/1),置于装有Dean-Stark装置的圆底烧瓶中,120℃-150℃加热回流,直到所有溶剂都被Dean-Stark装置收集,再向反应介质中加入甲苯和哌啶,重复3-5次,TLC跟踪至原料反应完全后,柱层析,减压蒸馏除去溶剂后,得到黑色固体产物NB;
(2)Aβ抑制剂(M)、DCC/DMAP按照摩尔比1:0.1~1/0.1~1溶解到氯仿中,加入1~1.3当量含有烷烃链的(M:M)Linker,50~100℃搅拌1~6h,25℃~60℃真空旋蒸除去溶剂,采用层析柱分离提纯,得到固体产物M-Ln。
(3)NB与M-Ln按照摩尔比1:1~3溶解到氯仿中,加入0.1~1当量(M:M)催化剂B,60~100℃搅拌1h~12h,室温~60℃真空旋蒸除去溶剂,采用层析柱分离提纯,反应结束后得到最终产物NB-Cn-M。
进一步地,所述NB的合成步骤:所述催化剂A为对甲苯磺酰胺。
优选地,所述M-Ln的合成步骤:DCC/DMAP为催化剂。
进一步地,所述M-Ln的合成步骤:所述Linker为丁二酸、己二酸、辛二酸以及壬二酸中的一种。
优选地,所述M-Ln的合成步骤:所述Aβ抑制剂(M)和linker的摩尔比为1:1~1.3。
进一步地,所述NB-Cn-M的合成步骤:所述催化剂B为DCC/DMAP,其摩尔比1:0.1~1/0.1~1。
与现有技术相比,本发明的有益效果是:
一、本发明采用近红外荧光探针与含有烷烃链的连桥侨联Aβ抑制剂通过酯化反应结合,其中近红外荧光特性区别于生物组织自身荧光信号,并对阿尔兹海默症早期发生的多肽区域突变位点FF有效识别结合呈现荧光,近红外荧光标记含有烷烃链连桥侨联的Aβ抑制剂后协同作用使得该近红外荧光探针能跨越血脑屏障,到达中枢神经系统,能够实现对AD早期诊疗一体化;
二、Aβ抑制剂不仅对Aβ寡聚体的形成有很好的抑制效果,还可以有效的破坏Aβ原纤维的稳定;
三、同时该探针制备温和,性能优异,有很好的潜在应用价值。
附图说明
图1是本发明得到的BODIPY类荧光探针NB-C2-K(kaempferol)的核磁氢谱图。
图2是本发明得到的BODIPY类荧光探针NB-C2-C(curcumin)的核磁氢谱图。
图3是本发明得到的BODIPY类荧光探针NB-C2-R(resveratrol)的核磁氢谱图。
图4是本发明得到的BODIPY类荧光探针NB-C2-K(resveratrol)对FF纳米纤维识别的荧光成像图。
具体实施方式
为使本发明实现的技术手段、创作特征、达成目的与功效易于明白了解,下面结合具体实施方式,进一步阐述本发明。
以下实施例1,例2与例3所用的NB制备方法,如下:
将甲基吡咯(1.0mmol)、对-乙羟基苯甲醛(0.5mmol)、和三乙胺(0.3ml)混合溶解到二氯甲烷中,室温搅拌过夜,0℃缓慢滴加三氟化硼乙醚(0.5ml),搅拌10分钟,加入2,3-二甲基-5,6-二氰基苯醌(0.5mmol),二氯甲烷萃取,无水Na2SO4干燥,60℃真空旋蒸除去溶剂,采用层析柱分离提纯,得到橙黄色固体产物BODIPY;
将BODIPY(0.5mmol)、4-N,N-二苯基胺苯甲醛(1.1mmol)、甲苯磺酰胺(0.1mmol)溶于10ml甲苯和哌啶的混合溶液中(v/v:1/1),置于装有Dean-Stark装置的圆底烧瓶中,140℃加热回流,直到所有溶剂都被Dean-Stark装置收集,再向反应介质中加入甲苯和哌啶,重复4次,TLC跟踪至原料反应完全后,柱层析,减压蒸馏除去溶剂后,得到黑色固体产物NB。
实施例1
将Aβ抑制剂山柰酚(0.3mmol)、DCC(0.02mmol)、DMAP(0.02mmol)溶解到氯仿中,加入丁二酸(0.3mmol),70℃搅拌3h,室温真空旋蒸除去溶剂,粗产品采用层析柱提纯,得到产物K-L2,所述化合物通过核磁1H NMR谱图进行表征,1H NMR(300MHz,DMSO-D6):δ=16.47(s,1H),12.18(s,1H),10.18(s,1H),9.68(s,1H),7.46-7.49(m,2H),6.61-6.67(m,2H),5.95-6.03(m,2H),2.59-3.01(m,4H).
将K-L2(0.5mmol)、DCC(0.01mmol)、DMAP(0.01mmol)溶解到氯仿中,加入NB(0.5mmol),70℃搅拌3h,30℃真空旋蒸除去溶剂,层析柱提纯,得到黑色固体产物NB-C2-K,所述化合物通过核磁1H NMR谱图进行表征,1H NMR(300MHz,DMSO-D6):δ=16.51(s,1H),10.08(s,1H),9.59(s,1H),7.77(m,4H),6.96-7.48(m,33H),6.65(m,2H),5.94-6.02(m,4H),5.67(m,1H),5.20(s,2H),2.61-2.71(m,4H),2.29(s,3H),1.95(s,3H)。
实施例2
将Aβ抑制剂姜黄素(0.1mmol)、DCC(0.01mmol)、DMAP(0.01mmol)溶解到氯仿中,加入丁二酸(0.1mmol),80℃搅拌2h,50℃真空旋蒸除去溶剂,层析柱提纯,得到产物C-L2,所述化合物通过核磁1H NMR谱图进行表征,1H NMR(300MHz,DMSO-D6):δ=12.18(s,1H),9.21(s,1H),7.77(d,J=7.5Hz,1H),7.60(d,J=7.5Hz,1H),7.02-7.30(m,6H),6.91(d,J=7.5Hz,1H),6.24(d,J=7.5Hz,1H),4.59(s,2H),3.86-3.87(m,6H),2.71-2.81(m,4H)。
将C-L2(0.2mmol)、DCC(0.01mmol)、DMAP(0.01mmol)溶解到氯仿中,加入NB(0.2mmol),60℃搅拌5h,室温真空旋蒸除去溶剂,层析柱提纯,得到黑色固体产物NB-C2-C,所述化合物通过核磁1H NMR谱图进行表征,1H NMR(300MHz,DMSO-D6):δ=9.21(s,1H),7.77(m,5H),7.60(d,J=7.5Hz,1H),6.90-7.24(m,37H),6.79(d,J=7.5Hz,1H),6.24(d,J=7.5Hz,1H),6.00-6.02(m,2H),5.67(d,J=7.5Hz,1H),5.20(s,2H),4.59(s,2H),3.86-3.87(m,6H),2.52(m,2H),2.29-2.32(m,5H),1.95(s,3H),1.64(m,4H)。
实施例3
将Aβ抑制剂白藜芦醇(0.3mmol)、DCC(0.03mmol)、DMAP(0.03mmol)溶解到氯仿中,加入丁二酸(0.3mmol),70℃搅拌6h,室温真空旋蒸除去溶剂,层析柱分离提纯,得到产物R-L2,所述化合物通过核磁1H NMR谱图进行表征,1H NMR(300MHz,DMSO-D6):δ=12.18(s,1H),9.07(s,2H),7.74(m,2H),7.33(m,2H),6.82-6.92(m,2H),6.38(s,2H),6.12(s,1H),2.71-2.81(m,4H)。
将R-L2(1mmol)、DCC(0.03mmol)、DMAP(0.03mmol)溶解到氯仿中,加入NB(1mmol),80℃搅拌10h,室温真空旋蒸除去溶剂,层析柱提纯,得到黑色固体产物NB-C2-K,所述化合物通过核磁1H NMR谱图进行表征,1H NMR(300MHz,DMSO-D6):δ=16.51(s,1H),10.08(s,1H),9.59(s,1H),7.77(m,4H),6.96-7.48(m,33H),6.65(m,2H),5.94-6.02(m,4H),5.67(m,1H),5.20(s,2H),2.61-2.71(m,4H),2.29(s,3H),1.95(s,3H)。
实施例中所制备NB-C2-K的应用:
NB-C2-K对二苯丙氨酸二肽纳米纤维识别分析:
AD早期发生的多肽区域突变位点位于Aβ的二苯丙氨酸二肽(Diphenylalanine,FF),在Aβ链上有3个FF,而位于Aβ的C-端疏水基的FF被确认为Aβ识别最小单位和核心;
利用刚果红染色后,FF自组装的有序结构具有类似Aβ结构的荧光双折射,说明FF包含了介导Aβ自组装成规则结构所需的全部分子信息;
在AD早期,Aβ发生β折叠,然后通过FFπ-π作用肩并肩堆积形成Aβ寡聚体(四聚体)时,FF几乎完全暴露,为探针与FF的有效结合创造了良好的机会,当Aβ发生聚集的作用点FF被探针占据时AD就会被抑制;NB-N=N-K对二苯丙氨酸二肽纳米纤维识别分析:
二苯丙氨酸二肽(3毫克)溶解在45μl六氟异丙醇中,然后注射加入105μL的二次水,室温下超声5分钟,二苯丙氨酸二肽自组装成纳米纤维,水透析除六氟异丙醇,得到二苯丙氨酸二肽纳米纤维储存在水中待用;
NB-C2-K(1毫克)溶解到45μL六氟异丙醇中,注射加入到二苯丙氨酸二肽纳米纤维水溶液中,2小时后,获得荧光标记二苯丙氨酸二肽纳米纤维。通过激光共聚焦荧光成像分析NB-N=N-K对二苯丙氨酸二肽纳米纤维识别荧光响应。
以上显示和描述了本发明的基本原理和主要特征和本发明的优点。本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明精神和范围的前提下,本发明还会有各种变化和改进,这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (7)
2.一种如权利要求1所述的烷烃链侨联Aβ抑制剂的荧光探针的制备方法,其特征在于,包括如下步骤:
(1)将甲基吡咯、对-乙羟基苯甲醛按照摩尔比2~3:1~1.5混合溶解到二氯甲烷中,加入1~1.3当量三乙胺(M:M),室温搅拌1h~6h,冰浴中缓慢滴加1~3当量的三氟化硼乙醚(M:M),搅拌0.5~3h,加入1~3当量的2,3-二甲基-5,6-二氰基苯醌,二氯甲烷萃取,无水Na2SO4干燥,真空除去溶剂,采用层析柱分离提纯,得到橙黄色固体产物BODIPY;
将BODIPY、4-N,N-二苯基胺苯甲醛、催化剂A按照摩尔比1~1.3:2~2.3:0.1~1溶于甲苯和哌啶的混合溶液中(v/v:1/1),置于装有Dean-Stark装置的圆底烧瓶中,120℃-150℃加热回流,直到所有溶剂都被Dean-Stark装置收集,再向反应介质中加入甲苯和哌啶,重复3-5次,TLC跟踪至原料反应完全后,柱层析,减压蒸馏除去溶剂后,得到黑色固体产物NB;
(2)Aβ抑制剂(M)、DCC/DMAP按照摩尔比1:0.1~1/0.1~1溶解到氯仿中,加入1~1.3当量含有烷烃链的(M:M)Linker,50~100℃搅拌1~6h,25℃~60℃真空旋蒸除去溶剂,采用层析柱分离提纯,得到固体产物M-Ln。
(3)NB与M-Ln按照摩尔比1:1~3溶解到氯仿中,加入0.1~1当量(M:M)催化剂B,60~100℃搅拌1h~12h,室温~60℃真空旋蒸除去溶剂,采用层析柱分离提纯,反应结束后得到最终产物NB-Cn-M。
3.权利要求2所述的一种烷烃链侨联Aβ抑制剂的荧光探针(NB-Cn-M)的制备方法,其特征在于:所述NB的合成步骤:所述催化剂A为对甲苯磺酰胺。
4.权利要求2所述的一种烷烃链侨联Aβ抑制剂的荧光探针(NB-Cn-M)的制备方法,其特征在于:所述M-Ln的合成步骤:DCC/DMAP为催化剂。
5.权利要求2所述的一种烷烃链侨联Aβ抑制剂的BODIPY类荧光探针的制备方法,其特征在于:所述M-Ln的合成步骤:所述Linker为丁二酸、己二酸、辛二酸以及壬二酸中的一种。
6.权利要求5所述的一种烷烃链侨联Aβ抑制剂的BODIPY类荧光探针的制备方法,其特征在于:所述M-Ln的合成步骤:所述Aβ抑制剂(M)和linker的摩尔比为1:1~1.3。
7.权利要求2所述的一种烷烃链侨联Aβ抑制剂的BODIPY类荧光探针的制备方法,其特征在于:所述NB-Cn-M的合成步骤:所述催化剂B为DCC/DMAP,其摩尔比1:0.1~1/0.1~1。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110799676.1A CN113549096A (zh) | 2021-07-15 | 2021-07-15 | 一种烷烃链侨联Aβ抑制剂的荧光探针及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110799676.1A CN113549096A (zh) | 2021-07-15 | 2021-07-15 | 一种烷烃链侨联Aβ抑制剂的荧光探针及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113549096A true CN113549096A (zh) | 2021-10-26 |
Family
ID=78131817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110799676.1A Pending CN113549096A (zh) | 2021-07-15 | 2021-07-15 | 一种烷烃链侨联Aβ抑制剂的荧光探针及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113549096A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113318116A (zh) * | 2021-06-17 | 2021-08-31 | 成都奥睿药业有限公司 | 姜黄素二氟硼及其衍生物的用途 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103709050A (zh) * | 2012-09-28 | 2014-04-09 | 中山大学 | 白藜芦醇衍生物及其在制备抗阿尔茨海默病药物中的应用 |
US20160202263A1 (en) * | 2015-01-14 | 2016-07-14 | Postech Academy-Industry Foundation | Novel pi-extended acedan derivatives, their application for two-photon microscopy imaging, and their application for two-photon microscopy imaging of amyloid-beta plaque in an alzheimer's disease animal model |
CN111440206A (zh) * | 2020-03-05 | 2020-07-24 | 淮阴工学院 | 一种近红外荧光探针bodipy类化合物及其制备方法 |
KR20200107658A (ko) * | 2019-03-08 | 2020-09-16 | 기초과학연구원 | 아밀로이드 베타 올리고머 및 플라크에 특이적인 이광자 프로브 및 pet용 추적자 |
CN112028915A (zh) * | 2020-09-11 | 2020-12-04 | 南京晓庄学院 | 一种荧光探针及其合成及应用 |
CN112592361A (zh) * | 2020-12-08 | 2021-04-02 | 江苏大学 | 氟硼吡咯功能化金属有机骨架材料及其制备方法和应用 |
CN112920113A (zh) * | 2021-01-22 | 2021-06-08 | 华南理工大学 | 一种靶向β淀粉样蛋白的荧光探针及制备以及其在阿尔兹海默症中的应用 |
-
2021
- 2021-07-15 CN CN202110799676.1A patent/CN113549096A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103709050A (zh) * | 2012-09-28 | 2014-04-09 | 中山大学 | 白藜芦醇衍生物及其在制备抗阿尔茨海默病药物中的应用 |
US20160202263A1 (en) * | 2015-01-14 | 2016-07-14 | Postech Academy-Industry Foundation | Novel pi-extended acedan derivatives, their application for two-photon microscopy imaging, and their application for two-photon microscopy imaging of amyloid-beta plaque in an alzheimer's disease animal model |
KR20200107658A (ko) * | 2019-03-08 | 2020-09-16 | 기초과학연구원 | 아밀로이드 베타 올리고머 및 플라크에 특이적인 이광자 프로브 및 pet용 추적자 |
CN111440206A (zh) * | 2020-03-05 | 2020-07-24 | 淮阴工学院 | 一种近红外荧光探针bodipy类化合物及其制备方法 |
CN112028915A (zh) * | 2020-09-11 | 2020-12-04 | 南京晓庄学院 | 一种荧光探针及其合成及应用 |
CN112592361A (zh) * | 2020-12-08 | 2021-04-02 | 江苏大学 | 氟硼吡咯功能化金属有机骨架材料及其制备方法和应用 |
CN112920113A (zh) * | 2021-01-22 | 2021-06-08 | 华南理工大学 | 一种靶向β淀粉样蛋白的荧光探针及制备以及其在阿尔兹海默症中的应用 |
Non-Patent Citations (3)
Title |
---|
CHAONAN LI,等: "Self-destructive PEG—BODIPY nanomaterials for photodynamic and photothermal therapy", 《J. MATER. CHEM. B》, vol. 7, no. 30, pages 176 * |
淮阴工学院: "阿尔兹海默症人工智能药物设计", pages 1 - 2, Retrieved from the Internet <URL:https://heec.cahe.edu.cn/school/science-project/1670.html> * |
阮班康,等: "AD荧光探针的最新研究进展", 《广东化工》, vol. 47, no. 17, pages 75 - 77 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113318116A (zh) * | 2021-06-17 | 2021-08-31 | 成都奥睿药业有限公司 | 姜黄素二氟硼及其衍生物的用途 |
CN113318116B (zh) * | 2021-06-17 | 2023-08-25 | 成都奥睿药业有限公司 | 姜黄素二氟硼及其衍生物的用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111440206B (zh) | 一种近红外荧光探针bodipy类化合物及其制备方法 | |
Si et al. | A curcumin-based NIR fluorescence probe for detection of amyloid-beta (Aβ) plaques in Alzheimer's disease | |
CN113549096A (zh) | 一种烷烃链侨联Aβ抑制剂的荧光探针及其制备方法 | |
EP0845457A1 (en) | 2,2-dideutero-5-aminolevulinic acid | |
CN108191789B (zh) | 一种吩噻嗪衍生物、其制备方法和应用 | |
CN111592472A (zh) | 一种荧光染料及其制备方法和用途 | |
CN109879884B (zh) | 一种检测粘度的荧光探针及其制备方法和应用 | |
CN109180556B (zh) | 一种部花菁类荧光化合物及其制备方法和应用 | |
US10004815B2 (en) | Near-infrared quenching group | |
Li et al. | Synthesis and evaluation of curcumin-based near-infrared fluorescent probes for detection of amyloid β peptide in Alzheimer mouse models | |
CN112851556B (zh) | 新型聚集诱导发光高尔基体荧光探针及其制备方法与应用 | |
WO2020238375A1 (zh) | 一种与Aβ寡聚体具有亲和力的荧光化合物及制备方法与应用 | |
KR101749808B1 (ko) | 알츠하이머병 조기 진단을 위한 섬유화된 타우에 결합하는 커큐민 기반 근적외선형광 탐침자 및 그 용도 | |
JP7157438B2 (ja) | アクロレインとの反応薬、その利用及び新規化合物 | |
CN114957293B (zh) | 用于特异性识别胰岛素的基于鸟嘌呤的花菁探针及其制备方法 | |
CN106045986A (zh) | 一种新型吩噻嗪衍生物及其制备方法与应用 | |
CN106008374A (zh) | 吡嗪类化合物及其在医药上的用途 | |
CN117186151B (zh) | 一种近红外两性离子花菁染料及其制备方法和应用 | |
CN113651840A (zh) | 一种-s-s-双硫键侨联抑制ad的小分子药物的荧光探针及其制备方法 | |
CN113620980A (zh) | 一种-N=N-双氮键侨联Aβ抑制剂的荧光探针及其制备方法 | |
CN114380856B (zh) | 用于脑部硫化氢检测的硅罗丹明衍生物及制备方法与应用 | |
CN116375752A (zh) | 一种含苯基苯并噻唑的bodipy二聚体荧光探针dff-bodipy及其制备方法和应用 | |
CN114736264B (zh) | Tau蛋白可视化PROTAC降解化合物及其制备方法和应用 | |
CN112552901A (zh) | 一种比率型锌离子荧光探针及其制备与应用 | |
CN116041244A (zh) | 靶向Aβ聚集物的姜黄素类AIE近红外荧光探针及其合成方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Quan Li Inventor after: Lin Yuebin Inventor after: Song Qinyong Inventor after: Yue Jiangtao Inventor before: Zhao Yingshi Inventor before: Quan Li Inventor before: Lin Yuebin Inventor before: Song Qinyong Inventor before: Yue Jiangtao |